Video: CVS/pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide
National Campaign runs from June 7 - 27 WOONSOCKET, R.I., June 8 /PRNewswire/ -- CVS/pharmacy has kicked-off its annual in-store fundraising campaign to support the fight against amyotrophic lateral sclerosis (ALS). Since 2002, CVS/pharmacy has partnered with the ALS Therapy Alliance (ATA) ...Prize4Life and the Alzheimer Research Forum Announce Launch of New Web-Portal for ALS Research
CAMBRIDGE, Mass., June 4 /PRNewswire-USNewswire/ -- Prize4life and the Alzheimer Research Forum announce the release of the ALS Forum ( www . ResearchALS.or g ), a web-based resource for researchers interested in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease or motor...The ALS Association's 'ALS Across America' Focuses On Staying Positive and Involved
For the second consecutive year during ALS Awareness Month, The ALS Association's "ALS Across America" campaign will recognize people throughout the United States living with amyotrophic lateral sclerosis for their courageous battle with Lou Gehrig's Disease. ...Jane H. Gilbert Appointed President and Chief Executive Officer of The ALS Association
Gilbert joins The Association after serving as the senior vice president for chapter operations for the American Red Cross in Washington, D.C. In that post, which she occupied from 2005-2008, Gilbert was responsible for eight service areas and 760 chapters, leading a professional team of more tha...Researchers identify ALS gene mutation
CHICAGO --- Research that has discovered a new gene whose mutations cause 5 percent of inherited cases of ALS (amyotrophic lateral sclerosis) is part of a national study led by the Northwestern University Feinberg School of Medicine. The study reported in Science today (Feb. 27) points to a c...Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials
ROCKVILLE, Md., Dec. 2 /PRNewswire-FirstCall/ -- Neuralstem Inc. (NYSE Alternext US: CUR) announced today that it has entered into a collaboration with the China Medical University & Hospital of Taiwan, to advance development of Neuralstem's human spinal cord neural stem cell therapies. The c...Neuralstem's ALS Trial on Clinical Hold
ROCKVILLE, Md., Feb. 20 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today its spinal cord stem cell trial to treat ALS is on clinical hold and that the Federal Drug Administration (FDA) has provided the Company with specific comments, questions and recommendations...Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
PITTSBURGH, Sept. 24 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") today announced the initiation of a Phase 1 clinical trial of KNS-760704, a small molecule therapy in development for the treatment of amyotrophic lateral sclerosis (ALS). (Logo: http://www.newscom.com/cgi-bin/prnh/20070...Neuralstem's Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
Make Synaptic Contact with Host Motor Neurons ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Transplanted human neural stem cells (hNSCs) developed by Neuralstem, Inc. (NYSE Alternext US: CUR) made synaptic contacts with the motor neurons of rats with ALS-like symptoms, a paper published i...Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
PITTSBURGH, Oct. 15 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation to KNS-760704 for the treatment of amyotrophic lateral sclerosis (ALS). (Logo: http://www.ne...Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Trophos Describes Identification, Characterization and Broad Neuroprotective Properties of TRO19622 in Journal of Pharmacology and Experimental Therapeutics Neurodegenerative Disease Specialists Publish Details of a Novel Drug Candidate for ALS That Targets Mitochondrial Proteins MARSEILLE, Ju...CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
LOS ANGELES--(BUSINESS WIRE)--Jun 25, 2007 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today reported safety and tolerability results from its previously announced double-blind, placebo-controlled, rising mul...CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced promising data from the six-month, open-label extension of its completed Phase IIa clinical trial with ar...AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis
...han Status for the treatment of Amyotrophic Lateral Sclerosis (ALS). als is the most common form of Motor Neuron Disease (MND), also known as Lou Ge...cebo controlled, Randomised Clinical Trial to determine whether later stage als patients with poor respiratory function can be seen to benefit from the med...Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
...health at 180 days post treatment. -- Initiation of repeat dosing Phase 2 clinical trials of SB-509 in stem cell mobilization (SB-509-703) and als (SB-509-801). -- Completion of enrollment and expansion of Phase 2 clinical trial in subjects with moderate to severe DN (SB-509-701). Present...Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
...ational New Drug) application with the FDA for the als trial in the next few weeks, and hopes to start th...ompany's cells have extended the life of rats with als (Lou Gehrig's disease) as reported the journal TRA...stigational New Drug) application with the FDA for als in the fall. Cautionary Statement Regarding Forw...IGF-I IRMA Test (With Extraction)
Description:...interaction of IGF-I with the Type 1 IGF receptor. The majority of IGF-I in blood is bound to a high molecular weight ternary complex with IGFBP-3 and als [1,2]. A smaller proportion of IGF-I circulates in association with other IGFBPs [2], and less than 5% is unbound or free IGF-I. It is believed that f...IGF-I ELISA Test (With Extraction)
Description:...interaction of IGF-I with the Type 1 IGF receptor. The majority of IGF-I in blood is bound to a high molecular weight ternary complex with IGFBP-3 and als [1,2]. A smaller proportion of IGF-I circulates in association with other IGFBPs [2], and less than 5% is unbound or free IGF-I. It is believed that f...IGF-I IRMA Test (Non-Extraction)
Description:...interaction of IGF-I with the Type 1 IGF receptor. The majority of IGF-I in blood is bound to a high molecular weight ternary complex with IGFBP-3 and als [1,2]. A smaller proportion of IGF-I circulates in association with other IGFBPs [2], and less than 5% is unbound or free IGF-I. It is believed that f...IGF-I ELISA Test (Non-Extraction)
Description:...interaction of IGF-I with the Type 1 IGF receptor. The majority of IGF-I in blood is bound to a high molecular weight ternary complex with IGFBP-3 and als [1,2]. A smaller proportion of IGF-I circulates in association with other IGFBPs [2], and less than 5% is unbound or free IGF-I. It is believed that f...Jefferson researcher awarded Landenberger Foundation grant for ALS research
PHILADELPHIA Piera Pasinelli, Ph.D., co-director of the Frances and Joseph Weinberg Unit for ALS Research at the Farber Institute for Neurosciences at Thomas Jefferson University was recently awarded a Margaret Q. Landenberger Research Foundation grant to identify why drug therapies that showed p...First trial in patients with a potential treatment of the incurable ALS muscle disease
Leuven (Belgium), Stockholm (Sweden) Permission has been granted to start the first safety and tolerability trial on patients for a remedy for ALS. ALS is an incurable, paralyzing neurodegenerative disorder that strikes 5 persons in every 100,000. The disease commonly affects healthy people in th...Swamping bad cells with good in ALS animal models helps sustain breathing
In a disease like ALS - one that's always fatal and that has a long history of research-resistant biology - finding a proof of principle in animal models is significant. This week, Johns Hopkins researchers report that transplanting a new line of stem cell-like cells into rat models of the dise...Hope among patients with ALS may take a variety of forms
New Rochelle, NY, March 27, 2008 -Sustaining hope in the face of a chronic, debilitating illness such as amyotrophic lateral sclerosis (ALS) should be a goal of palliative care and can take many forms, representing a continuum from focusing on the self to concern for others, as described in a pape...New stem cell research could reduce number of animal experiments
...n muscles, affecting breathing and eventually causing death. Dr Subramanian will be making iPS cells from the skin cells of patients suffering from als to study the genes that are thought to cause the disease. She said: "These are exciting times for stem cell research and there is tremendous potent...Jet-propelled imaging for an ultrafast light source
...f orienting the droplets can be advised. Nevertheless, Spence's group recently obtained excellent diffraction patterns of MS2 virus capsids at the als by subtracting the diffraction "noise" of the liquid jet itself. These capsids are the shells of the virus lacking its RNA genome and have the regular...UMMS researchers isolate first 'neuroprotective' gene in patients with amyotrophic lateral sclerosis
...use new methods in genetics to understand ALS." als is a progressive, neurodegenerative disorder affec...is estimated to account for 5 percent of inherited als cases. There are only four genes known, that when ...300,000 genetic variants in over 1,800 people with als and nearly 2,200 unaffected controls. The approach...Caffeine appears to be beneficial in males -- but not females -- with Lou Gehrig's disease
...ften death within five years of symptoms. Although als (Lou Gehrig's disease) was discovered over a centu...cluding oxidative stress. Coffee, Caffeine and als Researchers agree that als is a multifactorial disease that involves a comple...Caffeine appears to be beneficial in males -- but not females -- with Lou Gehrig's disease
...ften death within five years of symptoms. Although als (Lou Gehrig's disease) was discovered over a centu...cluding oxidative stress. Coffee, Caffeine and als Researchers agree that als is a multifactorial disease that involves a comple...Bay Area Youth to Represent ALS Patients at Giants' and Angels' Baseball Games on July 4th
SAN FRANCISCO, July 3 /PRNewswire-USNewswire/ -- Tomorrow, Corey Reich, an ALS patient from Piedmont, California, will attend both the San Francisco Giants and Los Angeles Angels of Anaheim baseball games this July 4th as a representative of the ALS Therapy Development Institute (ALS TDI). Corey ...Seminar Will Bring ALS Researchers to Patient Groups
The Leading ALS Lab Presents on Therapy Development Strategy CAMBRIDGE, Mass., Feb. 17 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) has announced the 2009 launch of its popular ALS Research 101 series. The two-hour, interactive seminar is designed to inform and ...Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
ROCKVILLE, Md., Sept. 8 /PRNewswire-FirstCall/ -- Neuralstem Inc., CEO, Richard Garr, will be a featured panelist discussing stem cells and ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at the 2008 World Stem Cell Summit in Madison, Wisconsin, on September 22, at 2:00 CDT. In a ...UW-Madison step in ALS research; student business plans; tech recycling
UW-Madison researchers may be moving toward a treatment for ALS, a nerve-system disease, using stem cells. Also, students excel at the G. Steven Burrill Technology Business Plan Contest, and Madison offers a computer and television recycling program. Original air date: Saturday, April 23, 2005 L...UW-Madison rat experiment could lead to stem-cell treatment for ALS
Madison, Wis. Scientists at the University of Wisconsin-Madison have sucessfully injected stem cells into rats' spines in a way that could lead to treatments for degenerative diseases but they did not use the controversial embryonic stem cells. The researchers inserted human stem cells deriv...Bilayer graphene gets a bandgap
...Source." Using infrared beamline 1.4 at the ALS, under the direction of als physicist Michael Martin and Zhao Hao of the Earth Sciences Division, Wang ...malleable electronic structure of bilayer graphene The results from the als measurements were obtained with relative ease and efficiency, and showed th...BASF Sues DuPont for Patent Infringement
...rporates BASF's patented promoter which is an important genetic component that enables successful tolerance toward an herbicide class known as AHAS or als inhibitors. BASF Plant Science GmbH seeks an injunction and damages against DuPont and its subsidiary Pioneer Hi-Bred International for this unla...Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States
... Non-Profit Biotech Calls on the Entire als Community to Join a Nationwide Network of Independ...IDGE, Mass., May 18 /PRNewswire-USNewswire/ -- The als Therapy Development Institute (ALS TDI) announced its BBQ For als Awareness , is a national initiative designed to i...Insmed Announces First Quarter 2009 Financial Results
... Generated $2.0 million in cost recovery revenue from the IPLEX(TM) EAP for als in Italy during the first quarter of 2009. ...se 2 results in MMD before the end of the second quarter. In addition, the als EAP is set to expand internationally via our agreement with IDIS, and we ar...